HEMATOLOGY

Brian Hill, MD, reviews the role of CAR T-cell therapy in mantle cell lymphoma.

Brian Hill, MD, reviews strategies for mitigating toxicities associated with CAR T-cell therapy.

Brian Hill, MD, reviews practice-changing data from the ZUMA-2 trial in patients with relapsed/refractory mantle cell lymphoma.

Brian Hill, MD, reviews second-line treatment options for patients with relapsed/refractory mantle cell lymphoma.

Brian Hill, MD, reviews frontline treatment options for patients with mantle cell lymphoma.

Brian Hill, MD, reviews the case of a 73-year-old man with mantle cell lymphoma.

Brian Hill, MD, reviews the case of a 73-year-old man with mantle cell lymphoma and discusses the latest data and treatment approaches.

JAK inhibitors designed for the treatment of myelofibrosis address the splenic response and constitutional symptoms associated with the disease, but the agents are inherently myelosuppressive and can exacerbate anemia and thrombocytopenia.

Ten-year overall survival is low among patients with acute myeloid leukemia , but an analysis demonstrated that survival is shorter for older patients treated with chemotherapy alone, according to published findings.

Treatment with the combination of eprenetapopt and azacitidine did not improve complete responses in patients with TP53-mutant myelodysplastic syndromes.

In a phase 1b clinical trial presented during the 2020 American Society of Hematology Annual Meeting, investigators sought to determine the efficacy and safety of the novel TIM-3–targeting IgG4 antibody sabatolimab in combination with hypomethylating agents as treatment of patients with acute myeloid leukemia, as well as high-risk myelodysplastic syndrome.

Multiple chimeric antigen receptor T-cell therapies for the treatment of lymphomas and multiple myeloma have moved forward in the regulatory process, with 1 new FDA approval in 2020 and others anticipated in the near future.

Justin M. Watts, MD, discusses the key takeaway from the phase 2 Study P-2001 clinical trial, a randomized study comparing the safety and efficacy of pevonedistat in combination with azacitidine in patients with high-risk myelodysplastic syndromes.

Experts in oncology and hematology review some of the most impactful FDA approvals from 2020 in lung, breast, blood, gastrointestinal, and genitourinary cancers.

The FDA updated the prescribing label for the approval of ibrutinib to include efficacy and safety data as combination therapy with rituximab as treatment of patients with Waldenström’s macroglobulinemia.

The novel CD123-targeting antibody-drug conjugate IMGN632 demonstrated promising clinical activity in a cohort of heavily pretreated patients with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm and had a favorable tolerability.

Key opinion leaders close the discussion by providing insight into their respective protocols for acute graft-vs-host (GVHD) disease prophylaxis.

A discussion on upcoming clinical trial data presentations featured at the American Society of Hematology (ASH) 2020 Annual Meeting.

Deepu Madduri, MD, details the efficacy data from the phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma. 

Expert physicians consider how ongoing developments will impact the treatment paradigm of graft-vs-host disease.

Considerations regarding current clinical practice patterns for transplant-ineligible myeloma and the uptake of newer data by health care professionals.

Deepu Madduri, MD, details the efficacy data from the phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma. 

Key opinion leaders provide community oncologists with advice for implementing the REACH2 regimen to manage patients with acute graft-vs-host disease (GVHD).

A review of the favorable safety data from CARTITUDE-1 for relapsed/refractory multiple myeloma.